Evidence map›Paper›PMID 39937729›Full record

ArticlePloS one2025

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

Zishan Jiwani, Simon B Goldberg, Jack Stroud, Jacob Young, John Curtin, John D Dunne, Otto Simonsson, Christian A Webb, Robin Carhart-Harris, Marco Schlosser

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zishan JiwaniDepartment of Counseling Psychology, University of Wisconsin, Madison, Wisconsin, United States of America.ORCID https://orcid.org/0000-0001-9054-8982
Simon B GoldbergDepartment of Counseling Psychology, University of Wisconsin, Madison, Wisconsin, United States of America.
Jack StroudDivision of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, United Kingdom.
Jacob YoungDepartment of Counseling Psychology, University of Wisconsin, Madison, Wisconsin, United States of America.
John CurtinCenter for Healthy Minds, University of Wisconsin, Madison, Wisconsin, United States of America.
John D DunneCenter for Healthy Minds, University of Wisconsin, Madison, Wisconsin, United States of America.
Otto SimonssonDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.ORCID https://orcid.org/0000-0003-4197-7566
Christian A WebbDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-8310-4539
Robin Carhart-HarrisDepartment of Neurology, University of California-San Francisco, San Francisco, California, United States of America.
Marco SchlosserDivision of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0634-0749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMeditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that psychedelics may benefit meditation practice. The present study examined individual, psychedelic-related, and meditation-related factors to determine under what conditions meditators perceive psychedelic use as beneficial for their meditation practice.

methodParticipants (N = 863) who had reported psychedelic use and a regular meditation practice (at least 3 times per week during the last 12 months) were included in the study. To accommodate a large number of variables, machine learning (i.e., elastic net, random forest) was used to analyze the data.

resultsMost participants (n = 634, 73.5%) found psychedelic use to have a positive influence on their quality of meditation. Twenty-eight variables showed significant zero-order associations with perceived benefits even following a correction. Elastic net had the best performance (R2 = .266) and was used to identify the most important features. Across 53 variables, the model found that greater use of psychedelics, intention setting during psychedelic use, agreeableness, and exposure to N,N-Dimethyltryptamine (N,N-DMT) were most likely to be associated with the perception that psychedelics benefit meditation practice. The results were consistent across several different approaches used to identify the most important variables (i.e., Shapley values, feature ablation). DISCUSSION: Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial. Longitudinal designs and randomized trials manipulating psychedelic use are needed to establish causality.

Indexed as

HallucinogensMeditationAdultFemaleHumansMaleMiddle AgedYoung AdultHallucinogens

Identifiers

PMID39937729
PMCPMC11819602

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.